Formoterol

also known as formoterol-fumarate · foradil · Foradil Aerolizer · formoterol fumarate dihydrate · Perforomist · PT005 · Atimos · FOR · +19 more

Other / unclassified

Developed for: asthma · chronic obstructive pulmonary disease · childhood onset asthma · chronic asthma · cough variant asthma · COVID-19 · exercise-induced bronchoconstriction · pulmonary emphysema
+14 more
· adult acute respiratory distress syndrome · bronchiectasis · chronic bronchitis · diabetic kidney disease · idiopathic pulmonary fibrosis · long COVID-19 · obesity disorder · obstructive lung disease · type 1 diabetes mellitus · type 2 diabetes mellitus · acute asthma · acute respiratory failure · Alzheimer disease · pneumonia
Investigated by: AstraZeneca · Chiesi Farmaceutici S.p.A. · Pearl Therapeutics, Inc. · Dey · Organon and Co · Novartis
+126 more
· Orion Corporation, Orion Pharma · Mundipharma Research Limited · Parexel · GlaxoSmithKline · Novartis Pharmaceuticals · SkyePharma AG · Zhujiang Hospital · Abbott · Boehringer Ingelheim · Eurofarma Laboratorios S.A. · University Hospital, Antwerp · Università degli Studi di Ferrara · Ache Laboratorios Farmaceuticos S.A. · Assistance Publique - Hôpitaux de Paris · Brigham and Women's Hospital · China-Japan Friendship Hospital · Hull University Teaching Hospitals NHS Trust · Morten Hostrup, PhD · Schering-Plough · Shenzhen People's Hospital · Tongji Hospital · University Hospital, Lille · Zambon SpA · Zunyi Medical College · Alkermes, Inc. · Alpha Bioresearch S.L. · Beijing Chao Yang Hospital · Beth Israel Deaconess Medical Center · Bispebjerg Hospital · Boston Children's Hospital · Branch of Shemyakin-Ovchinnikov Institute of Bioorganic chemistry of RAS · British Columbia Cancer Agency · Bugra Kerget · CISCRP · Central South University · Centre Hospitalier Intercommunal Creteil · Centre Hospitalier Universitaire, Amiens · Chongqing Songshan Hospital · Cipla Ltd. · ClinResearch, GmbH · Cognizant Technology Solution · Columbia University · Corporate Translations Inc · Dey, L.P. · Dialysis Clinic, Inc. · Dynamic Solutions · Esteve · Fasa University of Medical Sciences · Federal State Budgetary Institution, Pulmonology Scientific Research Institute · First Hospital of China Medical University · Fondazione Salvatore Maugeri · Guangdong Provincial Hospital of Traditional Chinese Medicine · Hat Yai Medical Education Center · Henan Provincial People's Hospital · Henan University of Traditional Chinese Medicine · Hormone Laboratory, Aker University Hospital, Oslo, Norway · Hospital General de Requena · Huashan Hospital · IQVIA Pty Ltd · Imperial College London · Inner Mongolia People's Hospital · Integrated Therapeutics Group · Johannes Gutenberg University Mainz · KU Leuven · Kindeva Drug Delivery · Laval University · MDS Pharma Services · MEDA Pharma GmbH & Co. KG · Mahidol University · Mayo Clinic · McGill University Health Centre/Research Institute of the McGill University Health Centre · Medical University of Lodz · Medical University of South Carolina · Menarini Group · all 132 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	DuoResp Spiromax	—	2014-04-28	europa.eu ↗
Label expansion	US (FDA)	FORADIL	—	2003-06-27	fda.gov ↗
Approved	US (FDA)	FORADIL	—	2001-02-16	fda.gov ↗

Trials 263 · started per year

today

US approved 2001

EU approved 2014

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 126 trials
Phase 1	NCT07433569	Mar → Jun 2026	asthma	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT06723756	Jan → Jun 2025	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT05898984	Apr → Jul 2023	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1	NCT05830071	Mar → Oct 2023	asthma, chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1	NCT04600505	Oct 2020 → May 2021	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT03906045	Apr 2019 → Mar 2020	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT03859414	Mar → Jul 2019	asthma, chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1	NCT03795350	Jan 2019 → Apr 2020	asthma, chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Terminated	No outcome recorded
Phase 1	NCT03740373	Sep → Oct 2018	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT03311373	Oct → Dec 2017	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT03250182	Aug → Dec 2017	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT02975843	Nov 2016 → Mar 2017	asthma, chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1	NCT02631941	Jan → Jul 2016	asthma	Zambon SpA	Completed	No outcome recorded
Phase 1	NCT03073057	Jan → Mar 2016	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT02237508	Sep 2014 → Feb 2015	asthma	Zambon SpA	Completed	No outcome recorded
Phase 1	NCT02197975	Aug → Oct 2014	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT02196714	Jul → Sep 2014	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT02119234	Mar 2014 → Feb 2015	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1	NCT01423305	Aug → Oct 2011	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT01386996	Jul → Nov 2011	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT01181063	Aug → Oct 2010	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT00657774	Apr → Sep 2008	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 1	NCT00569712	Jan 2007 → Dec 2008	lung cancer, precancerous condition	British Columbia Cancer Agency	Completed	No outcome recorded
Phase 1	NCT00418509	Nov 2006 → ?	—	Novartis	Completed	No outcome recorded
Phase 1	NCT00940329	Apr → Jul 2004	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00280358	? → Dec 2005	—	Dey	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT06110403	Sep 2023 → Sep 2026 expected	chronic obstructive pulmonary disease	University Hospital, Lille	Recruiting	No outcome recorded
Phase 1/2	NCT01176747	Aug → Sep 2010	asthma, chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 247 trials
Phase 2	NCT07301736	Dec 2025 → Jun 2027 expected	asthma	Chiesi Farmaceutici S.p.A.	Recruiting	No outcome recorded
Phase 2	NCT07022418	Dec 2025 → Dec 2026 expected	diabetic kidney disease	Medical University of South Carolina	Recruiting	No outcome recorded
Phase 2	NCT04087590	Jan 2020 → Mar 2023	chronic obstructive pulmonary disease	University Hospital, Lille	Terminated	No outcome recorded
Phase 2	NCT03590379	Jun → Oct 2018	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT03276078	Nov 2017 → Jun 2018	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT03086460	Sep 2017 → Jul 2018	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT03108534	Feb → Sep 2017	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT02787967	Aug 2016 → Jun 2017	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT02796651	Jun → Dec 2016	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT02196077	Aug 2014 → Mar 2015	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT02148120	Apr → Oct 2014	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT02048644	Mar 2014 → Apr 2015	idiopathic pulmonary fibrosis	Hull University Teaching Hospitals NHS Trust	Completed	No outcome recorded
Phase 2	NCT01783821	Jul 2013 → Jul 2015	adult acute respiratory distress syndrome	Mayo Clinic	Completed	No outcome recorded
Phase 2	NCT01615874	Jan → Sep 2013	asthma	Organon and Co	Withdrawn	No outcome recorded
Phase 2	NCT01738087	Nov 2012 → Jan 2013	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT01641081	Jun 2012 → Feb 2013	asthma	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT01650441	Apr 2012 → Jun 2013	asthma	University Hospital, Antwerp	Completed	No outcome recorded
Phase 2	NCT01468272	Nov 2011 → Aug 2012	childhood onset asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT01349816	Jun → Nov 2011	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT01349257	May → Jun 2011	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT01349803	May → Nov 2011	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT01258803	Dec 2010 → Oct 2011	asthma	Organon and Co	Completed	No outcome recorded
Phase 2	NCT01256086	Dec 2010 → Jul 2011	asthma	MEDA Pharma GmbH & Co. KG	Completed	No outcome recorded
Phase 2	NCT01191424	Oct 2010 → Sep 2011	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT01136655	Sep 2010 → Dec 2011	asthma	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT01168310	Aug 2010	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT01043601	Jul 2010 → Apr 2011	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Withdrawn	No outcome recorded
Phase 2	NCT01113593	May 2010	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT01048333	Jan → May 2010	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00801684	Feb → Apr 2009	chronic obstructive pulmonary disease	Alkermes, Inc.	Completed	No outcome recorded
Phase 2	NCT00746330	Aug 2008 → Apr 2009	asthma	Novartis	Completed	No outcome recorded
Phase 2	NCT00624754	Mar 2008 → Jul 2012	obstructive lung disease	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT01343745	Feb → Aug 2008	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT00635882	Feb 2008 → Jun 2009	asthma	Organon and Co	Completed	No outcome recorded
Phase 2	NCT00626522	Feb → Nov 2008	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00443482	Feb → May 2007	asthma	Novartis	Completed	No outcome recorded
Phase 2	NCT00403286	Nov 2006 → May 2007	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT00314509	Jul 2005 → Jan 2006	asthma	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00215358	Jul → Oct 2002	asthma	Dey	Completed	No outcome recorded
Phase 2	NCT00215371	Jul → Oct 2002	asthma	Dey	Completed	No outcome recorded
Phase 2	NCT02238119	Feb → Aug 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02242240	Mar → Dec 2001	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00239278	Jan 2001 → Jan 2005	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00215423	? → Dec 2003	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT00215397	? → Feb 2003	asthma	Dey	Completed	No outcome recorded
Phase 2	NCT00215384	? → Apr 2003	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT00215410	? → Oct 2003	asthma	Dey	Completed	No outcome recorded

Phase 2/34 trials
Phase 2/3	NCT04331470	Apr 2020	COVID-19	Fasa University of Medical Sciences	Unknown	No outcome recorded
Phase 2/3	NCT02693769	Jul → Oct 2016	asthma	Mundipharma Research Limited	Terminated	No outcome recorded
Phase 2/3	NCT02195375	Sep 2014 → May 2016	chronic obstructive pulmonary disease	Mundipharma Research Limited	Completed	No outcome recorded
Phase 2/3	NCT00463567	Apr 2007 → Aug 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 3115 trials
Phase 3	NCT05735431	Jun 2026 → Nov 2027	chronic asthma	Eurofarma Laboratorios S.A.	Withdrawn	No outcome recorded
Phase 3	NCT06429475	Jun 2024 → Dec 2028 expected	asthma	University of KwaZulu	Recruiting	No outcome recorded
Phase 3	NCT06075095	Jan 2024 → Aug 2025	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT05755906	Feb 2023 → Nov 2024	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT05573464	Sep 2022 → Mar 2024	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT05322707	Apr 2022 → Aug 2023	asthma	Cipla Ltd.	Completed	No outcome recorded
Phase 3	NCT05202262	Jan 2022 → Feb 2025	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT04705727	Aug → Sep 2021	childhood onset asthma	Centre Hospitalier Intercommunal Creteil	Terminated	No outcome recorded
Phase 3	NCT04876677	May 2021 → Jan 2022	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT04609904	Mar 2021 → Mar 2025	asthma	AstraZeneca	Completed	No outcome recorded
Show all 115 trials opens the full record — a long page
Phase 454 trials
Phase 4	NCT06531798	Dec 2025 → Oct 2026 expected	chronic obstructive pulmonary disease	AstraZeneca	Recruiting	No outcome recorded
Phase 4	NCT07073950	Nov 2025 → May 2027 expected	chronic obstructive pulmonary disease	AstraZeneca	Recruiting	No outcome recorded
Phase 4	NCT06590740	Oct 2024 → Sep 2025	cough variant asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT05970263	Jan 2024 → Dec 2025	chronic obstructive pulmonary disease	AstraZeneca	Withdrawn	No outcome recorded
Phase 4	NCT06571942	Nov 2023 → Jan 2025 overdue	chronic obstructive pulmonary disease	National Institute of Respiratory Diseases, Mexico	Recruiting	No outcome recorded
Phase 4	NCT05084222	Nov 2021 → Jun 2023	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 4	NCT04671355	Oct → Dec 2021	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Withdrawn	No outcome recorded
Phase 4	NCT04655170	Dec 2020 → Jan 2023 overdue	chronic obstructive pulmonary disease	University of Tennessee Graduate School of Medicine	Recruiting	No outcome recorded
Phase 4	NCT04159519	Jul 2020 → Jan 2023	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT04271839	Jun 2020 → May 2021	chronic asthma	Mundipharma Pharmaceuticals S.L.	Withdrawn	No outcome recorded
Phase 4	NCT04171180	May → Sep 2020	cough variant asthma	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 4	NCT03662711	Nov 2018 → Oct 2022	chronic obstructive pulmonary disease	Università degli Studi di Ferrara	Terminated	No outcome recorded
Phase 4	NCT03478696	Jun 2018 → Mar 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03563001	Jun → Sep 2018	chronic obstructive pulmonary disease	Zhujiang Hospital	Unknown	No outcome recorded
Phase 4	NCT03551197	Jun → Sep 2018	chronic obstructive pulmonary disease	Zhujiang Hospital	Unknown	No outcome recorded
Phase 4	NCT02934945	Sep 2015 → Jan 2017	asthma	Zhujiang Hospital	Unknown	No outcome recorded
Phase 4	NCT03028701	Sep 2015 → Mar 2017	chronic obstructive pulmonary disease	Neutec Ar-Ge San ve Tic A.Ş	Completed	No outcome recorded
Phase 4	NCT02424344	Apr 2015 → Jul 2016	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT02574975	Apr 2015 → May 2016	asthma	Zhujiang Hospital	Unknown	No outcome recorded
Phase 4	NCT04520230	Oct 2014 → Dec 2019	chronic obstructive pulmonary disease	Tanta University	Completed	No outcome recorded
Phase 4	NCT01853787	Jul 2014 → Jun 2015	chronic obstructive pulmonary disease	University of Milan	Completed	No outcome recorded
Phase 4	NCT01892787	Jul 2013 → Dec 2014	asthma	University of Dundee	Completed	No outcome recorded
Phase 4	NCT01845025	May 2013 → May 2016	chronic asthma	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT01794780	Feb 2013 → May 2015	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01488019	Mar 2012 → Jan 2016	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 4	NCT01712854	Mar → Sep 2012	chronic obstructive pulmonary disease	Columbia University	Terminated	No outcome recorded
Phase 4	NCT01471340	Jan 2012 → Nov 2016	asthma	Organon and Co	Completed	No outcome recorded
Phase 4	NCT01760304	Jan → Jul 2012	chronic obstructive pulmonary disease	Brigham and Women's Hospital	Terminated	No outcome recorded
Phase 4	NCT01620099	Nov 2011 → Apr 2014	asthma	Università degli Studi di Ferrara	Completed	No outcome recorded
Phase 4	NCT01466712	Nov 2011 → Dec 2014	pulmonary emphysema	KU Leuven	Unknown	No outcome recorded
Phase 4	NCT01397890	Jul 2011 → Jun 2013	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT01344655	Apr 2011 → Sep 2012	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 4	NCT01329276	Jun → Nov 2010	chronic obstructive pulmonary disease	University Hospital, Antwerp	Completed	No outcome recorded
Phase 4	NCT00997477	Jun → Jul 2010	asthma	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 4	NCT01070888	Feb 2010 → Apr 2014	exercise-induced bronchoconstriction	Boston Children's Hospital	Terminated	No outcome recorded
Phase 4	NCT00914654	Jul 2009 → Dec 2010	asthma	Bispebjerg Hospital	Unknown	No outcome recorded
Phase 4	NCT00939341	Jul 2009 → Aug 2010	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00901368	May 2009 → Sep 2010	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 4	NCT00910793	Aug 2008 → Aug 2010	asthma	Wilfried De Backer	Completed	No outcome recorded
Phase 4	NCT00702325	Jun 2008 → Sep 2009	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00633776	Mar 2008 → Jan 2009	chronic bronchitis, pulmonary emphysema	University of California, Los Angeles	Withdrawn	No outcome recorded
Phase 4	NCT00546234	Nov 2007 → Jan 2014	asthma	University of Alberta	Withdrawn	No outcome recorded
Phase 4	NCT01186653	Oct 2007 → May 2010	chronic obstructive pulmonary disease	Hull University Teaching Hospitals NHS Trust	Completed	No outcome recorded
Phase 4	NCT00489853	Jul 2007 → Aug 2008	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00561886	Apr → Oct 2007	chronic obstructive pulmonary disease	Johannes Gutenberg University Mainz	Completed	No outcome recorded
Phase 4	NCT00379028	Sep 2006 → Jul 2007	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT01089322	Dec 2005 → Apr 2009	asthma	Rafael Stelmach	Completed	No outcome recorded
Phase 4	NCT00139932	Sep 2005 → Nov 2006	chronic obstructive pulmonary disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00134979	Oct 2004 → Nov 2005	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00272753	Apr 2004 → Nov 2005	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00327353	Jan 2004 → ?	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00239421	Nov 2003 → Sep 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00490243	Jul 2003 → Oct 2006	asthma	Medical University of Lodz	Completed	No outcome recorded
Phase 4	NCT00479739	Nov 2002 → Jul 2004	asthma	GlaxoSmithKline	Completed	No outcome recorded

Phase not applicable15 trials
—	NCT07595796	Jun 2026 → Feb 2028 expected	—	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Not yet recruiting	No outcome recorded
—	NCT06865040	Jul 2025 → Mar 2028 expected	—	Centre Hospitalier Universitaire, Amiens	Recruiting	No outcome recorded
—	NCT07232264	Mar → Sep 2025	asthma	Bugra Kerget	Completed	No outcome recorded
—	NCT06597682	Mar 2025 → Jul 2027 expected	long COVID-19	Huashan Hospital	Not yet recruiting	No outcome recorded
—	NCT06105671	Jan → Jul 2024	—	Morten Hostrup, PhD	Completed	No outcome recorded
—	NCT05888350	Apr 2023 → Apr 2025	—	The First Affiliated Hospital of Guangzhou Medical University	Completed	No outcome recorded
—	NCT05553184	Jul 2022 → May 2023	obesity disorder, type 2 diabetes mellitus	University of Sherbrooke	Completed	No outcome recorded
—	NCT04616261	Nov 2020 → Nov 2022	—	University of Copenhagen	Unknown	No outcome recorded
—	NCT04137029	Apr 2019 → Jul 2020	reactive airway disease	Federal State Budgetary Institution, Pulmonology Scientific Research Institute	Unknown	No outcome recorded
—	NCT03565302	Jun 2018 → May 2021	hypertrophia musculorum vera	Morten Hostrup, PhD	Unknown	No outcome recorded
—	NCT02415179	May 2015 → Feb 2016	asthma	Mahidol University	Completed	No outcome recorded
—	NCT01457716	Oct → Nov 2011	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
—	NCT01194479	Aug 2010 → Aug 2014	type 1 diabetes mellitus	Yale University	Completed	No outcome recorded
—	NCT00159263	Nov 2004 → Nov 2006	asthma	Imperial College London	Completed	No outcome recorded
—	NCT00728715	Jan 2004 → Jan 2005	bronchiectasis	Hospital General de Requena	Completed	No outcome recorded

Also used as a comparator or background therapy in 144 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT01257048 Comparator	Aug 2011 → Jun 2012	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 15 trials
Phase 1	NCT06297668 Comparator	Apr → Jun 2024	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT02934607 Comparator	Nov 2016 → Mar 2017	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT02403713 Comparator	Aug → Oct 2014	asthma	Mundipharma Research Limited	Completed	No outcome recorded
Phase 1	NCT02287272 Comparator	May → Jul 2014	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1	NCT01398111 Comparator	May → Aug 2011	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT05689983 Comparator	Apr 2022 → Dec 2025 overdue	childhood onset asthma	Washington University School of Medicine	Active not recruiting	No outcome recorded
Phase 1/2	NCT03319043 Background	Nov 2017 → Dec 2018	cough variant asthma	Shanghai University of Traditional Chinese Medicine	Unknown	No outcome recorded
Phase 232 trials
Phase 2	NCT07633314 Comparator	Jul → Dec 2026 expected	chronic obstructive pulmonary disease	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 2	NCT07450482 Comparator	Jul → Sep 2025	chronic obstructive pulmonary disease	Joincare Pharmaceutical Group Industry Co., Ltd	Completed	No outcome recorded
Phase 2	NCT06676319 Background	Nov 2024 → Jun 2027 expected	asthma	Sanofi	Active not recruiting	No outcome recorded
Phase 2	NCT02500784 Comparator	Jan 2023 → Apr 2025	Alzheimer disease	Palo Alto Veterans Institute for Research	Withdrawn	No outcome recorded
Phase 2	NCT04937543 Comparator	Jun → Oct 2021	COVID-19	UPECLIN HC FM Botucatu Unesp	Completed	No outcome recorded
Phase 2	NCT02573233 Background	Jan 2016 → Jan 2018	asthma	Sanofi	Completed	No outcome recorded
Phase 2	NCT02833480 Comparator	Feb 2015 → Jan 2021	chronic obstructive pulmonary disease	University of British Columbia	Unknown	No outcome recorded
Phase 2	NCT02000609 Comparator	Dec 2013 → Apr 2014	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT01803087 Comparator	Feb → Oct 2012	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT01551888 Comparator	Jan → Mar 2012	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT01584492 Comparator	Dec 2011 → Feb 2013	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT01349868 Comparator	May → Jul 2011	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT01120093 Comparator	May → Aug 2010	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT01085045 Comparator	Mar → Nov 2010	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT01078623 Comparator	Feb → Sep 2010	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT01013753 Comparator	Feb 2010 → Jan 2011	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT01049360 Comparator	Dec 2009 → Aug 2010	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00995800 Comparator	Oct 2009 → Jul 2010	asthma	Mundipharma Research Limited	Completed	No outcome recorded
Phase 2	NCT00989833 Comparator	Sep 2009 → Jul 2010	exercise-induced bronchoconstriction	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT01848769 Comparator	Sep 2009 → Dec 2010	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT00961155 Comparator	Aug 2009 → Dec 2013	asthma	Medical University of Lodz	Unknown	No outcome recorded
Phase 2	NCT00929708 Comparator	Jun 2009 → Mar 2010	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00868023 Comparator	Feb → Jul 2009	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT00774761 Comparator	Nov 2008 → Apr 2009	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT00734292 Comparator	Sep 2008	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 2	NCT00736489 Comparator	Aug → Dec 2008	asthma, obstructive lung disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00706914 Comparator	Jun → Nov 2008	chronic obstructive pulmonary disease	AstraZeneca	Terminated	No outcome recorded
Phase 2	NCT00545272 Comparator	Oct 2007 → Apr 2008	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00557466 Comparator	Oct 2007 → May 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 2	NCT00830102 Comparator	Oct 2004 → Jan 2005	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 2	NCT00742248 Comparator	Sep 2004 → May 2005	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT00658255 Comparator	Oct 2002 → May 2003	asthma	AstraZeneca	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT06657066 Background	Dec 2021 → Apr 2022	asthma	King Edward Medical University	Completed	No outcome recorded
Phase 361 trials
Phase 3	NCT07318350 Comparator	Oct 2026 → Mar 2028 expected	—	Eurofarma Laboratorios S.A.	Not yet recruiting	No outcome recorded
Phase 3	NCT06234345 Comparator	Sep 2026 → Aug 2028 expected	chronic obstructive pulmonary disease	Eurofarma Laboratorios S.A.	Not yet recruiting	No outcome recorded
Phase 3	NCT06283966 Background	Feb 2024 → Dec 2027 expected	chronic obstructive pulmonary disease	AstraZeneca	Recruiting	No outcome recorded
Phase 3	NCT06067828 Comparator	Oct 2023 → Jan 2026	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT04233190 Comparator	Apr 2023 → Oct 2024	asthma	Eurofarma Laboratorios S.A.	Completed	No outcome recorded
Phase 3	NCT04191447 Comparator	Jul 2022 → Jul 2023	asthma	EMS	Unknown	No outcome recorded
Phase 3	NCT04320342 Background	Apr 2022 → Jan 2026	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT04886999 Background	Feb 2022 → Feb 2023	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT04193878 Comparator	Jun 2020 → Jul 2025	acute respiratory failure, pneumonia	Stanford University	Terminated	No outcome recorded
Phase 3	NCT04208581 Background	Oct 2019 → Dec 2021	chronic obstructive pulmonary disease, respiratory failure	Peking University People's Hospital	Unknown	No outcome recorded
Phase 3	NCT03836677 Background	Feb → Nov 2019	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT03846570 Comparator	Jan 2019 → Jul 2022	bronchiectasis	Erasmus Medical Center	Terminated	No outcome recorded
Phase 3	NCT03573817 Background	May → Sep 2018	chronic obstructive pulmonary disease	Mylan Inc.	Completed	No outcome recorded
Phase 3	NCT03081247 Background	Apr → Dec 2018	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Withdrawn	No outcome recorded
Phase 3	NCT03197818 Comparator	Dec 2016 → May 2020	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT02676089 Comparator	Apr 2016 → May 2018	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT02676076 Comparator	Feb 2016 → May 2018	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT02536508 Background	Aug 2015 → Sep 2017	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 3	NCT02497001 Comparator	Aug 2015 → Jan 2018	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 3	NCT02446418 Comparator	Jul 2015 → Jul 2017	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02465567 Background	Jun 2015 → Jul 2019	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 3	NCT02157935 Comparator	Jun 2014 → Feb 2016	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT02165826 Background	May 2014 → Sep 2015	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01917331 Background	Mar 2014 → Jan 2016	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT01946620 Comparator	Oct 2013 → Apr 2016	chronic obstructive pulmonary disease	Mundipharma Research Limited	Completed	No outcome recorded
Phase 3	NCT01803555 Comparator	Jul 2013 → Mar 2014	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT01574651 Comparator	May 2012 → Apr 2013	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01572792 Comparator	Apr 2012 → Jun 2013	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01511367 Comparator	Mar 2012 → Sep 2013	asthma	Mundipharma Research Limited	Completed	No outcome recorded
Phase 3	NCT01566149 Comparator	Mar → Sep 2012	asthma	Organon and Co	Completed	No outcome recorded
Phase 3	NCT01462942 Comparator	Oct 2011 → Jan 2013	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01437540 Comparator	Sep 2011 → Mar 2013	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01475032 Comparator	Sep 2011 → Sep 2012	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT01351792 Background	Sep 2011 → Nov 2012	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Terminated	No outcome recorded
Phase 3	NCT01437397 Comparator	Sep 2011 → Feb 2013	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01290874 Comparator	Mar 2011 → Jul 2013	asthma	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 3	NCT01602523 Comparator	Mar 2011 → Apr 2014	pulmonary emphysema	Temple University	Unknown	No outcome recorded
Phase 3	NCT01001364 Comparator	Feb 2010 → Apr 2011	asthma	Eurofarma Laboratorios S.A.	Completed	No outcome recorded
Phase 3	NCT01069289 Comparator	Jan 2010 → Mar 2011	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00929851 Comparator	Oct 2009 → Mar 2012	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT00932646 Comparator	Jun 2009 → May 2010	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00931385 Comparator	Jun 2009 → Apr 2010	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00849095 Comparator	Apr 2009 → Apr 2013	asthma	Università degli Studi di Ferrara	Completed	No outcome recorded
Phase 3	NCT00793624 Comparator	Feb 2009 → Dec 2010	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00796653 Comparator	Jan 2009 → Dec 2010	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00734318 Comparator	Sep 2008 → Jun 2009	asthma	Mundipharma Research Limited	Completed	No outcome recorded
Phase 3	NCT00563056 Comparator	Sep 2007 → Apr 2008	asthma	Mundipharma Research Limited	Completed	No outcome recorded
Phase 3	NCT00419757 Comparator	Jan 2007 → Jun 2008	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00393458 Comparator	Oct 2006 → Jul 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 3	NCT00383721 Comparator	Sep 2006 → Jul 2010	chronic obstructive pulmonary disease	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00393991 Comparator	Jul 2006 → Apr 2008	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 3	NCT00394199 Comparator	Jun 2006 → Feb 2008	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 3	NCT00393952 Comparator	Jun 2006 → Apr 2008	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 3	NCT00314574 Background	Dec 2005 → Nov 2009	asthma	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT00628758 Background	Dec 2005 → Sep 2008	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00250679 Comparator	Oct 2005 → Oct 2007	bronchitis, pulmonary emphysema	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 3	NCT00972140 Comparator	Aug 2005 → Apr 2006	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT00413387 Comparator	Sep 2004 → Aug 2005	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT00476268 Comparator	Feb 2004 → Jan 2005	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT00651547 Comparator	Jul 2002 → Oct 2003	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00652002 Comparator	Jul 2002 → Jan 2004	asthma	AstraZeneca	Completed	No outcome recorded

Phase 431 trials
Phase 4	NCT07666490 Comparator	Jun 2026 → Jun 2028 expected	asthma	Chiesi Farmaceutici S.p.A.	Not yet recruiting	No outcome recorded
Phase 4	NCT07052942 Comparator	Aug 2025 → Nov 2029 expected	acute asthma	DARTNet Institute	Recruiting	No outcome recorded
Phase 4	NCT06282861 Comparator	Feb 2024 → Jan 2025	chronic obstructive pulmonary disease	Fundacio Privada Mon Clinic Barcelona	Terminated	No outcome recorded
Phase 4	NCT06272370 Comparator	Feb → Sep 2024	asthma, hypersensitivity reaction disease, obstructive lung disease, respiratory tract infectious disorder	DARTNet Institute	Completed	No outcome recorded
Phase 4	NCT07133880 Comparator	Dec 2023 → Dec 2025 overdue	chronic obstructive pulmonary disease	University of Tennessee Graduate School of Medicine	Recruiting	No outcome recorded
Phase 4	NCT05596721 Background	Jan 2023 → Mar 2024	asthma, lung disorder	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 4	NCT06869382 Background	Jan → Dec 2023	asthma	Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation	Completed	No outcome recorded
Phase 4	NCT04737655 Comparator	Feb 2021 → Feb 2023	chronic obstructive pulmonary disease	PARZIBUT Gilles	Unknown	No outcome recorded
Phase 4	NCT03788395 Comparator	Jan 2019 → Jan 2020	asthma	Istituto per la Ricerca e l'Innovazione Biomedica	Completed	No outcome recorded
Phase 4	NCT03842904 Comparator	Dec 2018 → Jul 2019	chronic obstructive pulmonary disease	Medicines Evaluation Unit Ltd	Completed	No outcome recorded
Phase 4	NCT02972476 Comparator	Dec 2016 → Jul 2019	chronic obstructive pulmonary disease	University of Dundee	Completed	No outcome recorded
Phase 4	NCT02988869 Comparator	Aug 2016 → Aug 2017	chronic obstructive pulmonary disease	Neutec Ar-Ge San ve Tic A.Ş	Completed	No outcome recorded
Phase 4	NCT02429765 Comparator	Oct 2015 → Aug 2018	chronic obstructive pulmonary disease	Queen's University	Completed	No outcome recorded
Phase 4	NCT02533505 Comparator	Aug 2015 → Aug 2016	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT02526758 Background	Apr 2015 → May 2016	chronic obstructive pulmonary disease	Zhujiang Hospital	Unknown	No outcome recorded
Phase 4	NCT02345993 Comparator	Jan → May 2015	acute asthma	National Institute of Respiratory Diseases, Mexico	Unknown	No outcome recorded
Phase 4	NCT02257372 Background	Sep 2014 → Mar 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02388373 Comparator	Jul 2014 → Feb 2016	asthma	Research in Real-Life Ltd	Completed	No outcome recorded
Phase 4	NCT01912872 Comparator	Nov 2013 → Aug 2015	allergic asthma	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT01787097 Comparator	Jan 2013 → Dec 2014	chronic obstructive pulmonary disease	Imperial College London	Completed	No outcome recorded
Phase 4	NCT01748279 Comparator	Dec 2012 → Apr 2013	chronic obstructive pulmonary disease	Medical University of Bialystok	Completed	No outcome recorded
Phase 4	NCT01404013 Comparator	Feb 2012 → Aug 2014	asthma	The First Affiliated Hospital of Guangzhou Medical University	Unknown	No outcome recorded
Phase 4	NCT01377428 Comparator	Sep 2011 → Feb 2012	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 4	NCT01108627 Comparator	Oct 2010 → Dec 2011	—	Nemours Children's Clinic	Withdrawn	No outcome recorded
Phase 4	NCT00900874 Comparator	Jan 2009 → May 2010	asthma	All India Institute of Medical Sciences	Unknown	No outcome recorded
Phase 4	NCT00867737 Comparator	Sep 2008 → Sep 2009	asthma	Allergy and Asthma Center of El Paso	Unknown	No outcome recorded
Phase 4	NCT00680056 Comparator	Nov 2007 → Dec 2008	chronic bronchitis, pulmonary emphysema	Federal University of São Paulo	Completed	No outcome recorded
Phase 4	NCT01225913 Background	Oct 2007 → Jun 2027 expected	asthma	Gelb, Arthur F., M.D.	Recruiting	No outcome recorded
Phase 4	NCT01255579 Comparator	Jul 2007 → Dec 2008	asthma	University of Brescia	Completed	No outcome recorded
Phase 4	NCT00460577 Comparator	Mar 2007 → Sep 2008	acute asthma	Novartis	Completed	No outcome recorded
Phase 4	NCT00996697 Comparator	Oct 2006 → Sep 2008	chronic obstructive pulmonary disease	Brian J Lipworth	Completed	No outcome recorded

Phase not applicable11 trials
—	NCT07329946 Background	Sep 2026 → Feb 2027 expected	chronic obstructive pulmonary disease	Pierachille Santus, MD, PhD	Not yet recruiting	No outcome recorded
—	NCT07058259 Background	Nov 2024 → Jun 2025 overdue	chronic obstructive pulmonary disease	Istanbul Medeniyet University	Active not recruiting	No outcome recorded
—	NCT04675463 Background	Dec 2020 → Jan 2023	chronic obstructive pulmonary disease	ShiYue Li	Unknown	No outcome recorded
—	NCT03258749 Comparator	Nov 2017 → Aug 2018	chronic obstructive pulmonary disease	Huashan Hospital	Unknown	No outcome recorded
—	NCT02790047 Background	Oct 2016 → Jan 2018	chronic obstructive pulmonary disease	Khon Kaen University	Unknown	No outcome recorded
—	NCT02291016 Comparator	Feb 2015 → Mar 2016	chronic obstructive pulmonary disease	University of Tennessee Graduate School of Medicine	Completed	No outcome recorded
—	NCT02257463 Comparator	Oct 2011 → Apr 2014	chronic obstructive pulmonary disease	Mansoura University	Completed	No outcome recorded
—	NCT01179152 Comparator	Sep 2010 → Oct 2011	acute asthma	Meir Medical Center	Unknown	No outcome recorded
—	NCT01117116 Comparator	Mar 2010 → Sep 2013	asthma	National Jewish Health	Completed	No outcome recorded
—	NCT00706446 Comparator	Jun 2008 → Jun 2010	asthma	Brigham and Women's Hospital	Terminated	No outcome recorded
—	NCT00643578 Comparator	Mar 2008 → Jan 2009	asthma	University of Florida	Completed	No outcome recorded

Press releases naming this drug 4 releases

Date	Issuer	Release
2023-07-31	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva viatris.com ↗
2022-03-16	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva viatris.com ↗
2021-06-22	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States tevapharm.com ↗
2021-03-08	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol viatris.com ↗

Evidence & citations 31 cited values

Every value below carries the sentence it was read from. 423 sources stand behind the page.

Field	Value	Cited text
Known as	formoterol	“This study investigated the efficacy and tolerability of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol)*, administered...” PMID 23870606 ↗ Jul 2013 280 “participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid...” NCT06272370 ↗ “Dual Therapy (LABA + LAMA): Patients receive a long-acting beta-agonist (LABA) such as Formoterol, Salmeterol, Olodaterol, Vilanterol, or Indacaterol, in combination with a...” NCT07058259 ↗ “Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg in Patients With Stable Asthma Using Bronchoprovocation With Methacholine as a Bioassay...” NCT01256086 ↗ “This study was conducted to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) administered through metered-dose inhaler (MDI) in patients with persistent...” PMID 20874458 ↗ Nov 2010 “A U.S., multicenter, five-way crossover study compared single doses of formoterol, a long-acting beta-agonist, via pMDI (2.25, 4.5, and 9 micrograms) or dry powder inhaler (12...” PMID 24717790 ↗ Mar 2014 “160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25...” NCT02631941 ↗ “160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25...” NCT02237508 ↗ “Primary objectives were to assess total systemic exposure (without charcoal) and lung exposure (with charcoal) of budesonide, glycopyrronium, and formoterol administered as BGF...” PMID 32253054 ↗ Apr 2020 “We evaluated the effects of the long acting bronchodilator components of the extrafine single inhaler triple therapy beclometasone dipropionate/formoterol/glycopyrronium...” PMID 33298062 ↗ Dec 2020 “Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics:...” NCT02165826 ↗ “This study will be conducted to establish the relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with and...” NCT02934607 ↗ “The study evaluated the efficacy of beclomethasone dipropionate/formoterol fumarate (BDP/FF) extrafine combination versus fluticasone propionate/salmeterol (FP/S) combination...” PMID 24621109 ↗ Mar 2014 “Formoterol fumarate is a long-acting beta2-agonist that is an effective bronchodilator for the maintenance management of patients with chronic obstructive pulmonary disease.” PMID 19124372 ↗ Aug 2008 “Study 2, a single-dose, open-label crossover study, was conducted to establish the pharmacokinetic (PK) profile of nebulized formoterol and confirm comparability to FA.” PMID 18655841 ↗ Jul 2008 “The potent inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting β2-agonist with a rapid onset of action, formoterol fumarate (formoterol)” PMID 23368897 ↗ Feb 2013 “To evaluate the efficacy of 2 formoterol doses added to budesonide as fixed combinations vs budesonide alone in children 6 to younger than 12 years with asthma.” PMID 28256307 ↗ Mar 2017 “Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)” NCT01570478 ↗ “Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP "extrafine" 400 µg plus FF 24 µg).” NCT01351792 ↗ “CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)” NCT00901368 ↗ “Fluticasone Propionate / Formoterol Fumarate (Flutiform®) 500/20 µg BID and 250/10 µg BID Versus Salmeterol / Fluticasone (Seretide®) 50/500 µg BID” NCT02195375 ↗ “inhaled dual therapy with budesonide/formoterol fumarate dihydrate with an MDI with a spacer versus a DPI in patients with COPD and low PIF” PMID 35815354 ↗ Jan 2022 “Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)” NCT02685293 ↗ “formoterol [a long-acting beta2-agonist (LABA)] and aclidinium bromide [a long-acting muscarinic antagonist (LAMA) or anticholinergic]” NCT02429765 ↗ “budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days” NCT01225913 ↗ “Participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy” NCT07052942 ↗ “a fixed high-dose combination of the inhaled corticosteroid budesonide and the long-acting β(2)-adrenoceptor agonist formoterol” PMID 22024920 ↗ Jan 2012 “A combination of budesonide and long acting beta agonist: Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg” NCT01712854 ↗ “PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.” NCT02197975 ↗ “combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination)” NCT01620099 ↗ “The present study investigated drug-drug interaction effects between inhaled formoterol and oral roflumilast.” PMID 21631929 ↗ Jun 2011 “Budesonide/Glycoperronium/formoterol fumarate pressurised inhalation suspension 160/7.2/4.8 μg per actuation” NCT06297668 ↗ “Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks” NCT04208581 ↗ “The combination of formoterol and budesonide (Symbicort ®, Astra Zeneca) will be studied in this project.” NCT01787097 ↗ “320 μg of budesonide and 9 μg of formoterol are administered from Bufomix Easyhaler as two inhalations.” NCT05084222 ↗ “beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days” NCT02048644 ↗ “Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.” NCT03788395 ↗ “receive formoterol 12mcg / budesonide 400mcg Eurofarma or Alenia® 12mcg / 400mcg during 12 weeks” NCT04233190 ↗ “formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg” NCT01089322 ↗ “Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time” NCT04675463 ↗ “Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension” NCT06283966 ↗ “6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol” NCT00910793 ↗ “6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol” NCT01204034 ↗ “Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)” NCT03081247 ↗ “Budesonide and Formoterol Fum arate Powder for Inhalation, 1 inhale, bid for 12w” NCT05596721 ↗ “Budesonide 160 mcg/Glycopyrrolate 7.2 mcg/Formoterol fumarate dehydrate 5 mcg” NCT06531798 ↗ “Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg” NCT05202262 ↗ “Symbicort® (Budesonide/Formoterol) Breath Actuated Metered Dose Inhaler” NCT01360021 ↗ “Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks” NCT01404013 ↗ “budesonide/formoterol (BD/FOR, branded) 200/6 mcg or 400/12 mcg” PMID 27334739 ↗ Jun 2016 “50 µg salmeterol twice daily or 12 µg formoterol twice daily.” NCT00314574 ↗ “the addition of formoterol to budesonide maintenance therapy” PMID 27579635 ↗ Sep 2016 “320 µg budesonide / 9 µg formoterol fumarate dihydrate” NCT01329276 ↗ “budesonide/formoterol/glycopyrronium 160/7.2/4.8 mcg” NCT07329946 ↗ “50/5ug (fluticasone/formoterol) 2 puffs twice daily” NCT01511367 ↗ “mometasone furoate (MF)/formoterol (F) combination” PMID 20678306 ↗ Jul 2010 “Symbicort = budesonide plus formoterol fumarate” NCT00867737 ↗ “Formoterol 6 mcg/fluticasone 125 mcg Eurofarma.” NCT05735431 ↗ “combination budesonide/formoterol” NCT04331054 ↗ “Formoterol 12 μg pMDI” NCT01344655 ↗ “Formoterol (inhaler)” NCT02790047 ↗ “Formoterol” NCT03662711 ↗ NCT04137029 ↗ NCT00238784 ↗ NCT04616261 ↗ NCT00215358 ↗ NCT01848769 ↗ NCT02415179 ↗ NCT00476268 ↗ NCT00379028 ↗ NCT01194479 ↗ NCT02573233 ↗ NCT01551888 ↗ NCT04671355 ↗ NCT00235911 ↗ NCT06657066 ↗ NCT02345161 ↗ NCT02062463 ↗ NCT00706914 ↗ NCT03387241 ↗ NCT01078623 ↗ NCT00706446 ↗ NCT00793624 ↗ NCT00242775 ↗ NCT03104634 ↗ NCT01845025 ↗ NCT01783821 ↗ NCT06597682 ↗ NCT03551197 ↗ NCT02403713 ↗ NCT03028701 ↗ NCT01290874 ↗ NCT00244608 ↗ NCT00476099 ↗ NCT03563001 ↗ NCT00658255 ↗ NCT01186653 ↗ NCT00385593 ↗ NCT00327353 ↗ NCT00997477 ↗ NCT00736489 ↗ NCT00507234 ↗ NCT01462942 ↗ NCT02753712 ↗ NCT02988869 ↗ NCT00476073 ↗ NCT01117116 ↗ NCT00489853 ↗ NCT00206154 ↗ NCT05888350 ↗ NCT00862264 ↗ NCT04271839 ↗ NCT07318350 ↗ NCT00206167 ↗ NCT02526758 ↗ NCT04655170 ↗ NCT03846570 ↗ NCT02934945 ↗ NCT02725242 ↗ NCT00290264 ↗ NCT00569712 ↗ NCT01572792 ↗ NCT03276078 ↗ NCT01912872 ↗ NCT00861926 ↗ NCT01255579 ↗ NCT02224157 ↗ NCT05553184 ↗ NCT00475813 ↗ NCT00449527 ↗ NCT02693769 ↗ NCT00413387 ↗ NCT00239421 ↗ NCT01377428 ↗ NCT01257048 ↗ NCT01457716 ↗ NCT01013753 ↗ NCT01120093 ↗ NCT07133880 ↗ NCT00383721 ↗ NCT05970263 ↗ NCT00662779 ↗ NCT00424008 ↗ NCT00139932 ↗ NCT00961155 ↗ NCT00419744 ↗ NCT01748279 ↗ NCT01049360 ↗ NCT01258803 ↗ NCT01917331 ↗ NCT00239278 ↗ NCT02424344 ↗ NCT00419757 ↗ NCT04171180 ↗ NCT00989833 ↗ NCT00628862 ↗ NCT01466712 ↗ NCT01398111 ↗ NCT00728715 ↗ NCT02500784 ↗ NCT01343745 ↗ NCT01397890 ↗ NCT01794780 ↗ NCT02149199 ↗ NCT00635882 ↗ NCT02345993 ↗ NCT00326053 ↗ NCT00939341 ↗ NCT01946620 ↗ NCT01048333 ↗ NCT00383435 ↗ NCT02238119 ↗ NCT00742248 ↗ NCT06590740 ↗ NCT01181063 ↗ NCT00536913 ↗ NCT07450482 ↗ NCT00497237 ↗ NCT00250679 ↗ NCT01574651 ↗ NCT02533505 ↗ NCT00490243 ↗ NCT01047553 ↗ NCT00796653 ↗ NCT01179152 ↗ NCT00159263 ↗ NCT02119234 ↗ NCT04331470 ↗ NCT00652392 ↗ NCT00651651 ↗ NCT06865040 ↗ NCT00652002 ↗ NCT01176747 ↗ NCT01836016 ↗ NCT00651547 ↗ NCT01423305 ↗ NCT01085045 ↗ NCT00914654 ↗ NCT03573817 ↗ NCT00702325 ↗ NCT00215410 ↗ NCT02477397 ↗ NCT00215397 ↗ NCT01001364 ↗ NCT00252785 ↗ NCT02291016 ↗ NCT00215384 ↗ NCT00252863 ↗ NCT00419952 ↗ NCT00460577 ↗ NCT01471340 ↗ NCT00443482 ↗ NCT01386996 ↗ NCT02574975 ↗ NCT07595796 ↗ NCT01602523 ↗ NCT07022418 ↗ NCT01584492 ↗ NCT00449501 ↗ NCT01803555 ↗ NCT03478696 ↗ NCT00626522 ↗ NCT01892787 ↗ NCT01070888 ↗ NCT01437540 ↗ NCT01676987 ↗ NCT01202084 ↗ NCT06105671 ↗ NCT01641081 ↗ NCT05689983 ↗ NCT01070784 ↗ NCT00319306 ↗ NCT04191447 ↗ NCT00680056 ↗ NCT03073057 ↗ NCT00288379 ↗ NCT00972140 ↗ NCT00900874 ↗ NCT00134979 ↗ NCT01566149 ↗ NCT02833480 ↗ NCT00314509 ↗ NCT00929708 ↗ NCT00381485 ↗ NCT01167010 ↗ NCT00272753 ↗ NCT00646594 ↗ NCT04193878 ↗ NCT00561886 ↗ NCT00646516 ↗ NCT00849095 ↗ NCT00646321 ↗ NCT07633314 ↗ NCT00393458 ↗ NCT04705727 ↗ NCT06429475 ↗ NCT06676319 ↗ NCT04520230 ↗ NCT02157935 ↗ NCT02388373 ↗ NCT00691951 ↗ NCT06571942 ↗ NCT00996697 ↗ NCT02242240 ↗ NCT04937543 ↗ NCT01069289 ↗ NCT00643578 ↗ NCT01393145 ↗ NCT00545272 ↗ NCT03258749 ↗ NCT03565302 ↗ NCT00259766 ↗ NCT00479739 ↗ NCT00259779 ↗ NCT01760304 ↗ NCT07433569 ↗ NCT06234345 ↗ NCT00557466 ↗ NCT00624754 ↗ NCT04087590 ↗ NCT00463567 ↗
Known as	Atimos	“Thus, the primary objective for the present study is to compare the two extremes of available long acting beta-agonist formulations - i.e. extra fine HFA formoterol ( Atimos )...” NCT01892787 ↗ 2 “BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)” NCT01803087 ↗ “Formoterol 12 μg pMDI (Atimos®)” NCT01344655 ↗
Known as	CHF 1531	“different doses of CHF 1531 pressurized metered dose inhaler (pMDI) containing formoterol fumarate” NCT03086460 ↗
Known as	F12D	“Formoterol fumarate 12 μg DPI (F12D)” NCT00746330 ↗
Known as	F12M	“Formoterol fumarate 12 μg pMDI (F12M)” NCT00746330 ↗
Known as	FF	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05898984 ↗
Known as	FF MDI	“Patients received GFF MDI 18/9.6 μg, glycopyrrolate (GP) MDI 18 μg, formoterol fumarate (FF) MDI 9.6 μg, or placebo MDI, twice-daily for 24 weeks.” PMID 32450869 ↗ May 2020 1 “Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)” NCT02343458 ↗
Known as	FFIS	“nebulized formoterol fumarate inhalation solution (Perforomist**, FFIS 20g BID)” PMID 19232039 ↗ Mar 2009
Known as	FOR	“twice-daily inhaled corticosteroid/long-acting β2-agonist therapy [budesonide/formoterol (BUD/FOR)] 400 µg/12 µg in patients with symptomatic COPD at risk of exacerbations” PMID 29313286 ↗ Jan 2018 2 “extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FOR), 100/6 μg pMDI, 2 inhalations BID, vs. FOR 12 μg pMDI, 1 inhalation BID” PMID 24953015 ↗ Jun 2014 “formoterol fumarate 12 microg twice-daily (FOR) plus TIO 18 microg once-daily” PMID 20580216 ↗ Jun 2010
Known as	foradil	“FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler.” NCT01108627 ↗ 10 “plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.” NCT00801684 ↗ “fluticasone plus formoterol (Flixotide Evohaler, pMDI, Flovent [HFA]; Foradil, DPI, Foradil Aerolizer) administered concurrently” PMID 23368897 ↗ Feb 2013 “long acting bronchodilators "foradil/spiriva" or combined LABD and inhaled steroids” NCT02257463 ↗ “Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.” NCT00460577 ↗ “Foradil inh kap 12 mcg/dosage, 60 caps” NCT00628758 ↗ NCT01108627 ↗ NCT06282861 ↗ NCT00932646 ↗ NCT00734318 ↗ NCT00931385 ↗
Known as	Foradil (aerosolizer dry powder formoterol fumarate)	“Foradil (aerosolizer dry powder formoterol fumarate)” NCT00633776 ↗
Known as	Foradil Aerolizer	“FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler.” NCT01108627 ↗ 7 “received nebulized formoterol fumarate (Perforomist inhalation solution; FFIS 20 microg) or DPI (Foradil Aerolizer; FA 12 microg), or placebo twice daily for 12 weeks.” PMID 18363201 ↗ Feb 2008 “fluticasone plus formoterol (Flixotide Evohaler, pMDI, Flovent [HFA]; Foradil, DPI, Foradil Aerolizer) administered concurrently” PMID 23368897 ↗ Feb 2013 “1 or 2 doses of formoterol, (Foradil Aerolizer 12 mcg/capsule) a long-acting bronchodilator” NCT00643578 ↗ “Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)” NCT00830102 ↗ “Drug: Formoterol Fumarate 12 mcg (Foradil Aerolizer)” NCT06865040 ↗ “Formoterol Fumarate 12 μg (Foradil® Aerolizer®)” NCT01085045 ↗ NCT01113593 ↗
Known as	Form	“The participants were then randomized to budesonide/formoterol (Bud + Form; 400/12 μg BID), fluticasone/salmeterol (Flu + Salm; 250/50 μg BID), or formoterol only (12 μg BID)...” PMID 34464242 ↗ Nov 2021 1 “Many studies have shown the superior efficacy of budesonide (BUD)/formoterol (FORM) maintenance and reliever therapy, but still lack evidence of its efficacy in Chinese asthma patients” PMID 22932169 ↗ Sep 2012
Known as	Formoterol (Pressair)	“Formoterol (Pressair®)” NCT02796651 ↗
Known as	formoterol fumarate dehydrate	“SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 μg)” NCT02062463 ↗ 1 “Budesonide 160 mcg/Glycopyrrolate 7.2 mcg/Formoterol fumarate dehydrate 5 mcg” NCT06531798 ↗
Known as	formoterol fumarate dihydrate	“GFF MDI is a long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combination of glycopyrronium (GP) and formoterol fumarate dihydrate (FF), delivered by a...” PMID 30218695 ↗ Sep 2018 4 “formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler” NCT03846570 ↗ “Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.” NCT03788395 ↗ NCT03015259 ↗ NCT05322707 ↗
Known as	Formoterol Fumarate Inhalation Aerosol	“Formoterol Fumarate Inhalation Aerosol” NCT02766608 ↗
Known as	formoterol fumarate metered dose inhaler (FF MDI)	“formoterol fumarate metered dose inhaler (FF MDI)” NCT01854658 ↗
Known as	Formoterol Furamate	“The Investigational Medicinal Product (IMP) consists of a combination of Budesonide (corticosteroid) and Formoterol Furamate (fast-acting β2 agonist) dihydrate.” NCT06429475 ↗
Known as	FORMOTEROL VIATRIS	“FORMOTEROL FUMARATE 12 µg pwd inhalation capsule (FORMOTEROL VIATRIS®)” NCT06865040 ↗
Known as	formoterol-fumarate	“BACKGROUND: This study evaluated the lung deposition and the distribution pattern in the airways of a fixed combination of beclometasone dipropionate (BDP) and formoterol...” PMID 29989511 ↗ Jul 2018 140 “The purpose of this study was to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related...” NCT01845025 ↗ “Glycopyrrolate/formoterol fumarate (GFF) metered dose inhaler (MDI) is a fixed-dose combination of the long-acting muscarinic antagonist (LAMA), glycopyrrolate (GP), and the...” PMID 29567116 ↗ Feb 2018 “An extrafine combination of beclometasone dipropionate (BDP) and formoterol fumarate (FF) via a pressurised metered-dose inhaler (pMDI) has been commercially available for some...” PMID 28065679 ↗ Jan 2017 “Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total...” NCT00747318 ↗ “The inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and the long-acting β2-agonist (LABA) formoterol fumarate (formoterol) are being made available as a...” PMID 21605396 ↗ May 2011 “The purpose of this study is to evaluate the safety and efficacy of inhaled formoterol fumarate (7.2 and 9.6 µg ex-actuator) compared to placebo and Foradil Aerolizer in...” NCT01043601 ↗ “Foster is a combination therapy containing beclometasone dipropionate (an inhaled corticosteroid, or ICS) and formoterol fumarate (a long-acting beta-agonist, or LABA), which...” NCT06869382 ↗ “formoterol fumarate, a long-acting β2-AR agonist given four hours following injury, when glomerular dysfunction is already established, restored glomerular structure,...” NCT07022418 ↗ “CHF 5993 is an extrafine 'triple therapy' combination of the long-acting muscarinic antagonist glycopyrronium bromide (GB), the long-acting β2-agonist formoterol fumarate (FF),...” PMID 27209586 ↗ Apr 2017 “BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9...” NCT06110403 ↗ “A Randomized, Double-blind, Placebo and Active-controlled, Incomplete Block Cross-over, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF 1531 pMDI...” NCT03086460 ↗ “Patients in the MDI group received Foster® metered-dose inhaler (MDI) containing beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg per actuation, administered as...” NCT07232264 ↗ “single-inhaler extrafine combination of beclometasone dipropionate (BDP; inhaled corticosteroid), formoterol fumarate (FF; long-acting β2 agonist), and glycopyrronium (G;...” PMID 31582314 ↗ Sep 2019 “A new pediatric fixed combination of beclometasone dipropionate (BDP) 50 μg and formoterol fumarate (FF) 6 μg via pressurized metered-dose inhaler (pMDI) (CHF1535, Chiesi,...” PMID 33404895 ↗ Jan 2021 “Fixed Combination of Beclometasone Dipropionate (BDP) 35 μg Plus Formoterol Fumarate (FF) 4 μg Versus the Free Combination of Licensed BDP DPI (Dry Powder Inhaler) and FF DPI...” NCT02787967 ↗ “SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations...” NCT00657774 ↗ “FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler.” NCT01108627 ↗ “free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).” NCT01468272 ↗ “Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.” NCT01466712 ↗ “Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) Administered Via Pressurized Metered-dose Inhaler (pMDI)” NCT02467452 ↗ “The fixed combination of extrafine beclomethasone dipropionate and formoterol fumarate (BDP/FF) pMDI (Foster(®)) is approved for treatment of adult asthmatic patients.” PMID 25088067 ↗ Aug 2014 “The potent inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting β2-agonist with a rapid onset of action, formoterol fumarate (formoterol)” PMID 23368897 ↗ Feb 2013 “Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler” NCT03453112 ↗ “Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.” NCT04159519 ↗ “Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose” NCT03197818 ↗ “Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)” NCT02343458 ↗ “SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation.” NCT00649025 ↗ “Participants receive Formoterol Fumarate Inhalation Solution 20 μg twice daily (morning and evening) via nebulizer for 14 days. (Open-label)” NCT07450482 ↗ “Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)” NCT02347072 ↗ “Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)” NCT02347085 ↗ “plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.” NCT00801684 ↗ “All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation.” NCT03319043 ↗ “extrafine fixed-dose combination of beclomethasone dipropionate (BDP) 200 µg and formoterol fumarate (FF) 6 µg per actuation” NCT01577082 ↗ “PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.” NCT02197975 ↗ “Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler” NCT02424344 ↗ “Glycopyrrolate (GP) and Formoterol Fumarate (FF) combination (GFF) metered dose inhaler (MDI), GP MDI, and FF MDI” NCT01970878 ↗ “Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)” NCT02196077 ↗ “fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide” NCT02676089 ↗ “Formoterol Fumarate Inhalation Aerosol - 4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID” NCT02727660 ↗ “Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID” NCT02766608 ↗ “CHF 1535 (Fixed Combination of Beclomethasone Dipropionate 100 µg Plus Formoterol Fumarate 6 µg Dry Powder)” NCT00868023 ↗ “CHF 1535, a fixed-dose combination of beclometasone dipropionate (100 µg) and formoterol fumarate (6 µg).” NCT03888131 ↗ “fixed-dose combination of budesonide/glycopyrrolate/formoterol fumarate (BGF) 160/9/4.8 μg per actuation” PMID 37607661 ↗ Aug 2023 “FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER” NCT01191424 ↗ “Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler” NCT02497001 ↗ “a fixed combination of beclometasone-dipropionate/formoterol-fumarate administered via pMDI with VHC” PMID 24746942 ↗ Apr 2014 “BDP (Beclometasone Dipropionate)/FF (Formoterol Fumarate)/GB (Glycopyrronium Bromide) 100/6/12.5 µg” NCT07301736 ↗ “fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation” NCT01349257 ↗ “Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg BID (320/19.2μg/day)” NCT05755906 ↗ “Nebulized Formoterol Fumarate (PERFOROMIST®) Administered in Sequence and as a Combined Solution” NCT03573817 ↗ “Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate 100/6 mcg and 200 mcg” NCT01738087 ↗ “Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD” PMID 33488071 ↗ Jan 2021 “fixed combination of Beclometasone Dipropionate (BDP) 100 µg / Formoterol Fumarate (FF) 6 µg” NCT01191424 ↗ “CHF1535 100/6 NEXThaler (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)” NCT03108534 ↗ “Budesonide/glycopyrronium/formoterol fumarate pressurized inhalation suspension, HFO” NCT06723756 ↗ “fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg” NCT01450774 ↗ “nebulized formoterol fumarate inhalation solution (Perforomist**, FFIS 20g BID)” PMID 19232039 ↗ Mar 2009 “PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol.” NCT03250182 ↗ “formoterol fumarate 12 microg twice-daily (FOR) plus TIO 18 microg once-daily” PMID 20580216 ↗ Jun 2010 “Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg” NCT05202262 ↗ “beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide” PMID 28385353 ↗ Apr 2017 “Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler” NCT04609904 ↗ “budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler” NCT04609878 ↗ “Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI)” NCT01615874 ↗ “beclometasone dipropionate /formoterol fumarate/glycopyrronium bromide” NCT05830071 ↗ “Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate” NCT00862394 ↗ “Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009” NCT03262012 ↗ “Mometasone Furoate/Formoterol Fumarate (MF/F, MK-0887A [SCH418131])” NCT02741271 ↗ “Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler” NCT03022097 ↗ “Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI” NCT01566149 ↗ “Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF)” NCT06075095 ↗ “Drug: Formoterol Fumarate 12 mcg (Foradil Aerolizer)” NCT06865040 ↗ “Formoterol Fumarate 12 micrograms Inhalation Powder” NCT05553184 ↗ “Budesonide, Glycopyrronium, and Formoterol Fumarate” NCT02536508 ↗ “Budesonide, Glycopyrronium and Formoterol Fumarate.” NCT03906045 ↗ “Budesonide, Glycopyrronium, and Formoterol Fumarate” NCT05573464 ↗ “Treatment with Glycopyrronium/Formoterol Fumarate” NCT03836677 ↗ “Inhaled Formoterol Fumarate 12 μg, twice per day” NCT01572792 ↗ “Formoterol Fumarate 12 μg (Foradil® Aerolizer®)” NCT01085045 ↗ “Formoterol fumarate 12 ųg BID via aerolizer/DPI” NCT00250679 ↗ “Glycopyrronium and Formoterol Fumarate” NCT02643082 ↗ “formoterol fumarate (FF) MDI 9.6 μg” PMID 32450869 ↗ May 2020 “formoterol fumarate (FF) MDI 9.6 µg” PMID 29950826 ↗ Jun 2018 “FF( Formoterol Fumarate)” NCT05898984 ↗ “Formoterol Fumarate” NCT02937584 ↗ NCT02196714 ↗ NCT00308191 ↗ NCT00403286 ↗ NCT03859414 ↗ NCT01113593 ↗ NCT00830102 ↗ NCT00774761 ↗ NCT01908140 ↗ NCT06067828 ↗ NCT00394368 ↗ NCT07666490 ↗ NCT00633776 ↗ NCT01658891 ↗ NCT00413387 ↗ NCT03740373 ↗ NCT02268396 ↗ NCT00280371 ↗ NCT00280358 ↗ NCT00383552 ↗ NCT01803087 ↗ NCT04876677 ↗ NCT02465567 ↗ NCT00215449 ↗ NCT00394199 ↗ NCT03795350 ↗ NCT00215436 ↗ NCT03162055 ↗ NCT00215423 ↗ NCT00383240 ↗ NCT00734292 ↗ NCT02796651 ↗ NCT04886999 ↗ NCT02975843 ↗ NCT00215371 ↗ NCT01437397 ↗ NCT02796677 ↗ NCT07073950 ↗ NCT02148120 ↗ NCT01650441 ↗ NCT01853787 ↗ NCT02446418 ↗ NCT04320342 ↗ NCT00746330 ↗ NCT01168310 ↗ NCT00929851 ↗ NCT00394121 ↗ NCT00393991 ↗ NCT01349868 ↗ NCT01475032 ↗ NCT04737655 ↗ NCT02972476 ↗ NCT03268226 ↗ NCT00995800 ↗ NCT00418509 ↗ NCT00393952 ↗
Known as	Oxeze	“Oxeze” NCT00546234 ↗
Known as	Oxis	“Oxis turbuhaler 4.5-9 mcg/dosage, 60 dosage” NCT00628758 ↗ 1 NCT06282861 ↗
Known as	Oxis Turbuhaler	“Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations.” NCT01836016 ↗ 2 “Oral Prednisolone + Formoterol (Oxis® Turbuhaler) During Two Weeks” NCT00259779 ↗ “Formoterol Alone (Oxis® Turbuhaler® 4.5 µg)” NCT00288379 ↗
Known as	Perforomist	“Nebulized Formoterol Fumarate (PERFOROMIST®) Administered in Sequence and as a Combined Solution” NCT03573817 ↗ 3 “nebulized formoterol fumarate inhalation solution (Perforomist**, FFIS 20g BID)” PMID 19232039 ↗ Mar 2009 “Revefenacin (YUPELRI) & Formoterol (Perforomist)” NCT04655170 ↗ NCT01488019 ↗
Known as	Perforomist (nebulized formoterol fumarate)	“Perforomist (nebulized formoterol fumarate)” NCT00633776 ↗
Known as	Perforomist inhalation solution	“received nebulized formoterol fumarate (Perforomist inhalation solution; FFIS 20 microg) or DPI (Foradil Aerolizer; FA 12 microg), or placebo twice daily for 12 weeks.” PMID 18363201 ↗ Feb 2008
Known as	PT005	“Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)” NCT02343458 ↗ 3 “Budesonide (BD; PT008) and formoterol fumarate (FF; PT005) in a metered-dose inhaler (MDI); (BFF MDI; PT009)” NCT02196077 ↗ “Formoterol Fumarate MDI (PT005; 7.2 and 9.6 µg Ex-actuator)” NCT01043601 ↗ “FF MDI (PT005)” NCT01970878 ↗
Action	Activate	“long-acting β(2)-adrenergic agonists” PMID 22383665 ↗ Aug 2012
Modality	Other / unclassified	“long-acting β(2)-adrenergic agonists” PMID 22383665 ↗ Aug 2012
Route	Inhaled	“Formoterol Inhalant Powder” NCT00159263 ↗